Donepezil

Generic Name: Donepezil

Brand Names: Adlarity, Aricept, Namzaric

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉NO_₃

CAS Number: 120014-06-4

Unique Ingredient Identifier: 8SSC91326P

Background: In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication: Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions: Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

Phase 2

Not yet recruiting

Conditions: Anorexia Nervosa

Interventions: Drug: Donepezil

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-26

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 10

Registration Number: NCT06518941

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers

Not Applicable

Not yet recruiting

Conditions: Alzheimer Disease
Cognitive Impairment

Interventions: Other: Acupuncture
Other: Sham Acupuncture
Drug: Donepezil

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 176

Registration Number: NCT06417086

Locations: 🇨🇳
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Phase 1

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: MK-1167
Drug: Donepezil
Drug: Placebo

First Posted Date: 2024-02-29

Last Posted Date: 2024-08-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 28

Registration Number: NCT06285240

Locations: 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida, United States
🇺🇸
CenExel iResearch, LLC ( Site 0003), Decatur, Georgia, United States
🇺🇸
CenExel iResearch, LLC ( Site 0004), Savannah, Georgia, United States

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Phase 2

Recruiting

Conditions: Osteoporosis

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2023-09-18

Last Posted Date: 2024-10-08

Lead Sponsor: Duke University

Target Recruit Count: 45

Registration Number: NCT06041789

Locations: 🇺🇸
Duke Memory Disorders Clinic, Durham, North Carolina, United States

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

Phase 2

Recruiting

Conditions: Mild Alzheimer Disease

Interventions: Drug: PM012
Drug: PM012 Placebo
Drug: Donepezil
Drug: Donepezil placebo

First Posted Date: 2023-04-13

Last Posted Date: 2023-04-18

Lead Sponsor: Mediforum Ltd., Co.

Target Recruit Count: 312

Registration Number: NCT05811000

Locations: 🇰🇷
Mediforum, Seoul, Seongdon-gu, Korea, Republic of

Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Phase 2

Not yet recruiting

Conditions: Parkinson Disease
Mild Cognitive Impairment

Interventions: Drug: Placebo
Drug: Donepezil Hydrochloride

First Posted Date: 2023-02-02

Last Posted Date: 2023-09-28

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 120

Registration Number: NCT05709301

Donepezil Prevents Urinary Retention After Extensive Total Hysterectomy

Early Phase 1

Conditions: Urinary Retention After Procedure

Interventions: Other: Usual care
Drug: Donepezil

First Posted Date: 2022-09-15

Last Posted Date: 2022-09-15

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 108

Registration Number: NCT05540977

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease

Phase 2

Recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: smart soup
Drug: Placebo
Drug: Donepezil
Drug: Memantine

First Posted Date: 2022-09-14

Last Posted Date: 2022-09-14

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 180

Registration Number: NCT05538507

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

Early Phase 1

Recruiting

Conditions: Bilateral Sensorineural Hearing Loss

Interventions: Drug: Donepezil
Drug: Placebo

First Posted Date: 2022-06-29

Last Posted Date: 2024-06-18

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 50

Registration Number: NCT05438264

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study

Phase 2

Completed

Conditions: Digestive Oncology
Supportive Care

Interventions: Drug: PLACEBO
Drug: DONEPEZIL

First Posted Date: 2022-02-24

Last Posted Date: 2024-04-05

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 77

Registration Number: NCT05254639

Locations: 🇫🇷
Hôpital privé d'Antony, Antony, France
🇫🇷
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
🇫🇷
CH d'Argenteuil, Argenteuil, France

and more 31 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy